Table 1.

Demographics and Main Clinical Features of the Study Population

	AMD Patients								Healthy Subjects
	Total (n = 90)			RPD (n = 30)		GA (n = 30)			Total (n = 30)
	Mean ± SD	P Valuea	Drusen (n = 30) Mean ± SD	Mean ± SD	P Valueb	Mean ± SD	P Valueb	P Valuec	Mean ± SD	P Valueb	P Valuec	P Valued
Age, y	76.6 ± 7.1	0.073	76.2 ± 8.9	78.2 ± 6.5	0.674	78.1 ± 5.2	0.719	1.000	74.0 ± 6.9	0.628	0.098	0.115
BCVA, logMAR	0.18 ± 0.25	<0.001	0.07 ± 0.08	0.13 ± 0.08	0.562	0.48 ± 0.33	<0.001	<0.001	0.05 ± 0.06	0.938	0.241	<0.001
Axial length, mm	23.62 ± 0.51	0.692	23.54 ± 0.46	23.59 ± 0.53	0.987	23.66 ± 0.52	0.840	0.959	23.69 ± 0.55	0.690	0.868	0.993
CMT, µm	233 ± 42	0.264	244 ± 27	234 ± 43	0.814	223 ± 57	0.214	0.707	230 ± 33	0.541	0.968	0.927
Subfoveal ChT, µm	191 ± 79	<0.001	171 ± 48	192 ± 88	0.637	148 ± 77	0.577	0.071	253 ± 60	<0.001	0.006	<0.001
Mean ChT, µm	184 ± 78	<0.001	161 ± 46	186 ± 88	0.516	143 ± 77	0.728	0.080	244 ± 55	<0.001	0.007	<0.001

n, number; SD, standard deviation; AMD, age-related macular degeneration; RPD, reticular pseudodrusen; GA, geographic atrophy; BCVA, best-corrected visual acuity; CMT, central macular thickness; ChT, choroidal thickness.

Statistical Analysis: Analysis of variance (ANOVA) for independent samples with Tukey post hoc analysis.

^aANOVA for independent samples.

^bComparison with drusen group.

^cComparison with RPD group.

^dComparison with GA group.